Abivax S.A. Stock Price, News & Analysis

Abivax (NASDAQ:ABVX), a clinical-stage biotechnology company focused on chronic inflammatory diseases, announced the full exercise of underwriters' option to purchase 1,523,400 additional American Depositary Shares (ADSs) at $64.00 per ADS.

The additional shares bring the total offering to 11,679,400 ADSs, resulting in gross proceeds of $747.5 million (€637.5 million) and estimated net proceeds of $700.3 million (€597.2 million). The offering price represents a 21.0% premium over the volume-weighted average price of Ordinary Shares on Euronext Paris over the last three trading sessions.

The closing is expected on July 28, 2025, with the net proceeds to be applied proportionally to the same purposes as the base offering.

Abivax (Euronext Paris: ABVX), a clinical-stage biotechnology company, announced the resumption of trading for its ordinary shares on Euronext Paris effective July 24, 2025, at 3:30 p.m. CEST.

The trading halt, which began at 9:00 a.m. CEST on the same day, was implemented to facilitate the allocation process and pricing announcement of the company's American Depositary Shares (ADS) offering in the United States. Each ADS represents one ordinary share with a nominal value of €0.01.

Abivax (NASDAQ:ABVX) has announced the pricing of its public offering of 10,156,000 American Depositary Shares (ADSs) at $64.00 per ADS, aiming to raise approximately $650 million. The company has also granted underwriters a 30-day option to purchase up to 1,523,400 additional ADSs.

The offering price represents a 21% premium over the volume-weighted average price of Ordinary Shares on Euronext Paris. The proceeds will primarily fund the clinical development of obefazimod for Ulcerative Colitis ($140-185 million) and Crohn's Disease ($30-65 million). Combined with current cash reserves of $71.4 million, this funding is expected to extend operations into Q4 2027.

The offering will result in approximately 16% dilution of share capital, or 18.4% if the underwriters' option is fully exercised. A 60-day lock-up period applies to both company executives and the company itself.

Abivax (Euronext Paris: ABVX), a clinical-stage biotechnology company, has announced a temporary trading halt of its ordinary shares on Euronext Paris starting July 24, 2025, at 9:00 a.m. CEST. The suspension is related to the company's previously announced public offering of American Depositary Shares (ADS) in the United States.

The trading halt will allow for investor allocation confirmations and pricing announcement of the U.S. offering. Each ADS represents one ordinary share with a nominal value of €0.01. Trading is expected to resume on the same day at approximately 3:30 p.m. CEST.

Abivax (NASDAQ:ABVX) has announced the launch of a significant $400 million (€340 million) public offering of American Depositary Shares (ADSs) in the United States. Each ADS represents one ordinary share of the company. The offering includes a 30-day option for underwriters to purchase up to 15% additional ADSs.

The company plans to use the proceeds primarily for: 23% for obefazimod development in Ulcerative Colitis, 5% for Crohn's Disease development, and 72% for working capital and general corporate purposes. As of June 30, 2025, Abivax had cash reserves of $71.4 million, sufficient to fund operations into Q4 2025.

Additionally, Heights Capital Management has submitted a notice to convert 150 convertible notes (€9.4 million) into 394,447 new ordinary shares at €23.7674 per share, with issuance expected around July 29, 2025.

Abivax (NASDAQ:ABVX) announced positive Phase 3 results from its ABTECT-1 and ABTECT-2 trials evaluating obefazimod, a first-in-class oral miR-124 enhancer, for treating moderate to severe ulcerative colitis. The 50mg once-daily dose achieved a compelling pooled 16.4% placebo-adjusted clinical remission rate at Week 8.

Key highlights include: 19.3% placebo-adjusted remission in ABTECT-1 and 13.4% in ABTECT-2, meeting all primary and secondary endpoints. The trials involved 1,275 patients across 600 sites in 36 countries, with 47.3% having inadequate response to prior advanced therapy. The drug demonstrated favorable safety with no new safety signals.

The company plans to submit FDA and EMA applications in H2 2026, pending successful maintenance trial results expected in Q2 2026.

Abivax (ABVX) held its annual general meeting on June 6, 2025, where shareholders approved all proposed resolutions. Key approvals included the 2024 financial statements, compensation policies for executives and directors, and financial transaction delegations to the Board. The meeting also ratified the appointments of Sylvie Grégoire as Chairman and Dominik Höchli, MD as a Board member. Abivax, a clinical-stage biotech company, focuses on developing therapeutics that leverage natural regulatory mechanisms to modulate inflammatory responses in chronic inflammatory diseases.

Abivax (ABVX) reported Q1 2025 financial results, showing increased operating losses of EUR 47.2M compared to EUR 44.7M in Q1 2024. R&D expenses rose by EUR 3.6M to EUR 39.3M, primarily due to Crohn's Disease clinical program progression and expanded R&D headcount. The company recorded a net loss of EUR 52.4M, up from EUR 42.9M in Q1 2024. Cash position decreased to EUR 103.6M from EUR 144.2M at year-end 2024, with current funding expected to sustain operations into Q4 2025. Notable operational progress includes completion of Phase 3 ABTECT trial enrollment for ulcerative colitis treatment and advancement of Crohn's Disease clinical programs.

Abivax has successfully completed enrollment for its Phase 3 ABTECT trials studying obefazimod in patients with moderate to severe ulcerative colitis. The trials exceeded their target by enrolling 1,275 participants (4% above target of 1,224).

Key timeline expectations include:

• Top-line results from 8-week induction trials in Q3 2025
• 44-week maintenance data in Q2 2026
• New Drug Application submission planned for H2 2026

The study's baseline characteristics match the Phase 2b trial profile, with 65% of participants having severe disease (MMS 7-9), 48% experiencing prior advanced therapy failure, and 42% using corticosteroids. The trial spans multiple regions, with significant participation from Eastern Europe (38%), Asia (24%), and Western/Central Europe (22%). The company's cash runway extends through the induction trials readout into Q4 2025.